District of Columbia Department of Health, Washington, DC, USA.
, 2201 Shannon Place, SE, Washington, DC, 20020, USA.
AIDS Behav. 2024 Aug;28(8):2598-2606. doi: 10.1007/s10461-024-04378-z. Epub 2024 May 27.
Pre-exposure prophylaxis (PrEP) is an effective tool for human immunodeficiency virus (HIV) prevention. The purpose of this study is to identify correlates of PrEP retention using patient data from an urban, publicly funded safety-net clinic in Washington, DC. Cox proportional hazards regression, logistical regression, and survival curves were used to assess the association of age, gender, race/ethnicity, insurance, number of partners, and sexually transmitted infection (STI) diagnosis at PrEP initiation with time on PrEP. From August 2016-December 2020, 1,126 people were prescribed PrEP - patients were mostly Black (44.8%) or Latinx (30.4%) and identified as cisgender men (84.6%). Half had no insurance (49.1%), with the remaining patients reporting private (28.9%) or public (21.5%) insurance. Age at PrEP prescription ranged from 15 to 66 with 80% being 20 to 39 years. For the 87.7% (n = 987) of patients who discontinued PrEP, mean PrEP time was 158 days and median was 28 days. The highest rates of discontinuation were observed within the first month with 44.3% discontinuing by day 30, 52.3% by 3 months, and 73.2% by 1 year. Cisgender women, transgender persons, and those younger than 30 years were more likely to discontinue PrEP. Latinx and patients with less than 3 male partners in the last 90 days were less likely to discontinue PrEP. We demonstrated a high level of PrEP uptake among populations disproportionally affected by HIV. Future analyses are needed to examine ways of reducing barriers to PrEP initiation and improving PrEP adherence.
暴露前预防(PrEP)是预防人类免疫缺陷病毒(HIV)的有效工具。本研究旨在利用华盛顿特区一家城市公共资助的安全网诊所的患者数据,确定 PrEP 保留的相关因素。使用 Cox 比例风险回归、逻辑回归和生存曲线评估 PrEP 开始时的年龄、性别、种族/民族、保险、性伴侣数量和性传播感染(STI)诊断与 PrEP 时间的关联。2016 年 8 月至 2020 年 12 月,共有 1126 人被开处 PrEP 处方-患者主要为黑人(44.8%)或拉丁裔(30.4%),并被确认为顺性别男性(84.6%)。有一半人没有保险(49.1%),其余患者报告有私人保险(28.9%)或公共保险(21.5%)。PrEP 处方年龄从 15 岁到 66 岁不等,80%为 20 至 39 岁。对于 87.7%(n=987)停止服用 PrEP 的患者,平均 PrEP 时间为 158 天,中位数为 28 天。在第一个月内观察到停药率最高,44.3%在第 30 天停药,52.3%在第 3 个月停药,73.2%在第 1 年内停药。顺性别女性、跨性别者和年龄小于 30 岁的人更有可能停止服用 PrEP。拉丁裔和在过去 90 天内性伴侣少于 3 人的患者不太可能停止服用 PrEP。我们证明了在受 HIV 影响不成比例的人群中 PrEP 的高使用率。需要进一步分析,以研究减少 PrEP 启动障碍和提高 PrEP 依从性的方法。